Sobi completes acquisition of emapalumab and related assets
Following approvals from relevant competition authorities Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has completed the acquisition of the newly established company owning emapalumab and related assets, as announced on 12 June 2019. The acquisition means that the previously announced exclusive licence agreement with Novimmune will be superseded. Through the acquisition of emapalumab, Sobi gains access to: · All assets relating to emapalumab including